Trial Profile
A Phase II, Open-label, Multi-Dose Study of the Monoclonal Antibody MDX-1097 in Previously Treated Kappa Light Chain Restricted Multiple Myeloma Subjects with Stable Measurable Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs KappaMab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 20 Jun 2011 New trial record
- 17 Jun 2011 An independent data monitoring committee has recommended that the trail be expanded to include up to 27 patients.